Der Browser den Sie verwenden ist sehr alt.

Wir können daher nicht sicherstellen, dass jede Funktion (Gestaltung, Bilder und zusätzliche Funktionen) dieser Internetseite im vollen Umfang zur Verfügung steht. Bitte nutzen Sie eine aktuellere Browserversion.
Wir bitten um Ihr Verständnis.
Startseite > Forschung > Studien > Aktuelle Studien > Mammakarzinom

Klinische Studien zum Mammakarzinom

  • CONTESSA TRIO A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly Patients with HER2 Negative, Locally Advanced or Metastatic Breast Cancer
    ID: 2018-004715-41
  • EDCP-BRCA
    EDCP-BRCA: Evaluation eines Decision Coaching Programms zur strukturierten Entschei-dungsunterstützung bei präferenzsensiblen Entscheidungen im Rahmen der risikoadap-tierten Prävention bei BRCA1/2 Mutationsträgerinnen
  • Gepar Douze
    A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
    ID: [2017-002771-25]
  • IRENE
    Incidence and Resolution of Eribulin-induced peripheral Neuropathy
    ID: EUPAS14118
  • NATALEE
    A phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant TriAl with Ribociclib [LEE011]: NATALEE)
    ID: 2018-002998-21
  • PADMA (GBG 93)
    A RANDOMIZED, OPEN-LABEL, MULTI-CENTER PHASE IV STUDY EVALUATING PALBOCICLIB PLUS ENDOCRINE TREATMENT VERSUS A CHEMOTHERAPY-BASED TREATMENT STRATEGY IN PATIENTS WITH HORMONE RECEPTOR POSITIVE / HERHer2 negative metastatic breast cancer in a real world setting
    ID: [2016-004482-89]
  • PATINA (AFT-38)
    A RANDOMIZED, OPEN LABEL, PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF PALBOCICLIB + ANTI-HER2 THERAPY + ENDOCRINE THERAPY VS. ANTI-HER2 THERAPY + ENDOCRINE THERAPY AFTER INDUCTION TREATMENT FOR HORMONE RECEPTOR POSITIVE (HR+) / HER2-POSITIVE METASTATIC BREAST CANCER
    ID: [2017-000419-17]
  • PreCycle
    A multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with Palbociclib and an aromatase inhibitor- or Palbociclib and Fulvestrant
    ID: [2016-004191-22]